A Phase 2 interventional study of Nivolumab and Ipilimumab in Pan Tumor, sponsored by Bristol-Myers Squibb. Completed at 60 sites in 17 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-08-28.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to demonstrate the clinical activity of nivolumab in combination with ipilimumab in multiple types of tumors based on their Tumor Mutational Burden status.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab · Biological: Ipilimumab
Biological: Nivolumab
Specified dose on specified days
Also known as: Opdivo, BMS-936558
Specified dose on specified days
Also known as: Yervoy, BMS-734016
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm A
ORR was defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) based on Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.
Time frame: From date of randomization up to 42 months
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm B
ORR was defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) based on Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.
Time frame: From date of randomization up to 57 months
Objective Response Rate (ORR) Per Investigator
ORR was defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) based on investigator assessment. Calculated using Clopper-Pearson method. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.
Time frame: From date of randomization up to 57 months
Duration of Response (DoR) Per Investigator
DoR was defined as the time from first confirmed complete or partial response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: CR= Disappearance of all target lesions. PR= ≥ 30% decrease in the sum of diameters of target lesions. PD= ≥ 20% increase in the sum of diameters of target lesions. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable/improved T2/FLAIR; off corticosteroids; stable/improved clinically PR= ≥ 50% decrease in the sum of diameters of all measurable enhancing lesions; no progression of nonmeasurable disease; no new lesions; stable/improved T2/FLAIR; stable/improved clinically. PD= ≥ 25% increase in sum of diameters of enhancing lesions, on stable/increasing doses of corticosteroids; significant increase in T2/FLAIR; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.
Time frame: From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)
Duration of Response (DoR) Per Blinded Independent Central Review (BICR)
DoR was defined as the time from first confirmed complete or partial response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: CR= Disappearance of all target lesions. PR= ≥ 30% decrease in the sum of diameters of target lesions. PD= ≥ 20% increase in the sum of diameters of target lesions. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable/improved T2/FLAIR; off corticosteroids; stable/improved clinically PR= ≥ 50% decrease in the sum of diameters of all measurable enhancing lesions; no progression of nonmeasurable disease; no new lesions; stable/improved T2/FLAIR; stable/improved clinically. PD= ≥ 25% increase in sum of diameters of enhancing lesions, on stable/increasing doses of corticosteroids; significant increase in T2/FLAIR; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.
Time frame: From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)
Time to Objective Response (TTR) Per Investigator
TTR is defined as the time from randomization date to the date of the first confirmed response (complete response (CR) or partial response (PR)), based on investigator assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.
Time frame: From date of randomization to date of first confirmed response (CR or PR) (Up to 57 months)
Time to Objective Response (TTR) Per Blinded Independent Central Review (BICR)
TTR is defined as the time from randomization date to the date of the first confirmed response (complete response (CR) or partial response (PR)), based on Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.
Time frame: From date of randomization to date of first confirmed response (CR or PR) (Up to 57 months)
Clinical Benefit Rate (CBR) Per Investigator
CBR is defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) or stable disease (SD) based on investigator assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm PR= ≥ 30% decrease in the sum of diameters of target lesions SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD RANO Criteria: CR= Disappearance of all enhancing disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions; stable or improved clinically SD= does not qualify for CR, PR, or progression; stable nonenhancing T2/FLAIR lesions
Time frame: From date of randomization up to 57 months
Clinical Benefit Rate (CBR) Per Blinded Independent Central Review (BICR)
CBR is defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) or stable disease (SD) per Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm PR= ≥ 30% decrease in the sum of diameters of target lesions SD= does not qualify for PR or progressive disease RANO Criteria: CR= Disappearance of all enhancing disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions; stable or improved clinically SD= does not qualify for CR, PR, or progression; stable nonenhancing T2/FLAIR lesions
Time frame: From date of randomization up to 57 months
Progression Free Survival (PFS) Per Investigator
PFS is defined as the time from randomization date to the date of the first documented tumor progression, determined by investigator assessment, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: Progressive Disease (PD)= ≥ 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of ≥ 5 mm. RANO Criteria: PD= ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement obtained either at baseline or best response, on stable or increasing doses of corticosteroids; significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.
Time frame: From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)
PFS is defined as the time from randomization date to the date of the first documented tumor progression, determined by Blinded Independent Central Review (BICR) assessment, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: Progressive Disease (PD)= ≥ 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of ≥ 5 mm. RANO Criteria: PD= ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement obtained either at baseline or best response, on stable or increasing doses of corticosteroids; significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.
Time frame: From date of randomization to date of first documented tumor progression, or date of death, whichever occurs first (Up to 57 months)
Overall Survival (OS)
OS is defined as the time between the date of randomization and the date of death due to any cause. Participants who did not have a date of death were censored on the last date for which a participant was known to be alive. Calculated using KM method.
Time frame: From date of randomization to date of death (Up to 57 months)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of participants with any grade adverse events (AEs), serious adverse events (SAEs), drug-related AEs, and drug-related SAEs by Tumor Mutational Burden- High (TMB-H) status using worst grade per national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) v5 criteria. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. TMB-H = ≥ 10 mutations per megabase bTMB-H and tTMB-H are not mutually exclusive
Time frame: From first dose to 30 days post last dose (Up to 25 months)
Number of Participants With On-Treatment Laboratory Parameters
Number of participants with grade 3-4 on-treatment laboratory parameters. Parameters include hematology, chemistry, liver function, and renal function using worst grade per national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) v5 criteria. Grade 3=Severe event Grade 4=Life threatening event TMB-H = ≥ 10 mutations per megabase bTMB-H and tTMB-H are not mutually exclusive
Time frame: From first dose to 30 days post last dose (Up to 25 months)
| Milestone | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Started | 136 | 76 |
| Btmb-h started | 80 | 45 |
| Ttmb-h started | 88 | 47 |
| Completed | 135 | 76 |
| Not completed | 1 | 0 |
| Withdrew: Disease progression | 1 | 0 |
| Milestone | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Started | 135 | 76 |
| Btmb-h started | 83 | 47 |
| Ttmb-h started | 94 | 50 |
| Arm b rollover | 0 | 22 |
| Completed | 0 | 0 |
| Not completed | 135 | 76 |
| Withdrew: Disease progression | 76 | 57 |
| Withdrew: Study drug toxicity | 19 | 1 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Adverse event unrelated to study drug | 4 | 3 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Participant request to discontinue study treatment | 3 | 1 |
| Withdrew: Maximum clinical benefit | 0 | 1 |
| Withdrew: Participants completed treatment | 27 | 11 |
| Withdrew: Other reasons | 2 | 1 |
ORR was defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) based on Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.
| Precentage of participants | Arm A: Nivolumab+Ipilimumab |
|---|---|
| Blood TMB-H (bTMB-H) | 22.5 (13.9 to 33.2) |
| Tissue TMB-H (tTMB-H) | 38.6 (28.4 to 49.6) |
ORR was defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) based on Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.
| Percentage of participants | Arm B: Nivolumab |
|---|---|
| Blood TMB-H (bTMB-H) | 15.6 (6.5 to 29.5) |
| Tissue TMB-H (tTMB-H) | 29.8 (17.3 to 44.9) |
ORR was defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) based on investigator assessment. Calculated using Clopper-Pearson method. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.
| Percentage of participants | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Blood TMB-H (bTMB-H) | 25.0 (16.0 to 35.9) | 13.3 (5.1 to 26.8) |
| Tissue TMB-H (tTMB-H) | 44.3 (33.7 to 55.3) | 23.4 (12.3 to 38.0) |
DoR was defined as the time from first confirmed complete or partial response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: CR= Disappearance of all target lesions. PR= ≥ 30% decrease in the sum of diameters of target lesions. PD= ≥ 20% increase in the sum of diameters of target lesions. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable/improved T2/FLAIR; off corticosteroids; stable/improved clinically PR= ≥ 50% decrease in the sum of diameters of all measurable enhancing lesions; no progression of nonmeasurable disease; no new lesions; stable/improved T2/FLAIR; stable/improved clinically. PD= ≥ 25% increase in sum of diameters of enhancing lesions, on stable/increasing doses of corticosteroids; significant increase in T2/FLAIR; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.
| Months | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Blood TMB-H (bTMB-H) | 27.96 (11.20 to NA) | NA (11.24 to NA) |
| Tissue TMB-H (tTMB-H) | NA (27.96 to NA) | NA (8.05 to NA) |
DoR was defined as the time from first confirmed complete or partial response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: CR= Disappearance of all target lesions. PR= ≥ 30% decrease in the sum of diameters of target lesions. PD= ≥ 20% increase in the sum of diameters of target lesions. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable/improved T2/FLAIR; off corticosteroids; stable/improved clinically PR= ≥ 50% decrease in the sum of diameters of all measurable enhancing lesions; no progression of nonmeasurable disease; no new lesions; stable/improved T2/FLAIR; stable/improved clinically. PD= ≥ 25% increase in sum of diameters of enhancing lesions, on stable/increasing doses of corticosteroids; significant increase in T2/FLAIR; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.
| Months | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Blood TMB-H (bTMB-H) | NA (10.15 to NA) | NA (5.52 to NA) |
| Tissue TMB-H (tTMB-H) | NA (33.51 to NA) | NA (8.31 to NA) |
TTR is defined as the time from randomization date to the date of the first confirmed response (complete response (CR) or partial response (PR)), based on investigator assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.
| Months | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Blood TMB-H (bTMB-H) | 3.48 ± 1.17 | 4.08 ± 3.40 |
| Tissue TMB-H (tTMB-H) | 3.56 ± 1.74 | 3.75 ± 2.50 |
TTR is defined as the time from randomization date to the date of the first confirmed response (complete response (CR) or partial response (PR)), based on Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR= ≥ 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. RANO Criteria: CR= Disappearance of all enhancing measurable and nonmeasurable disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; and stable or improved clinically.
| Months | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Blood TMB-H (bTMB-H) | 3.59 ± 1.65 | 4.33 ± 2.93 |
| Tissue TMB-H (tTMB-H) | 4.37 ± 5.10 | 3.98 ± 2.47 |
CBR is defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) or stable disease (SD) based on investigator assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm PR= ≥ 30% decrease in the sum of diameters of target lesions SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD RANO Criteria: CR= Disappearance of all enhancing disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions; stable or improved clinically SD= does not qualify for CR, PR, or progression; stable nonenhancing T2/FLAIR lesions
| Percentage of participants | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Blood TMB-H (bTMB-H) | 42.5 (31.5 to 54.1) | 40.0 (25.7 to 55.7) |
| Tissue TMB-H (tTMB-H) | 63.6 (52.7 to 73.6) | 46.8 (32.1 to 61.9) |
CBR is defined as the percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) or stable disease (SD) per Blinded Independent Central Review (BICR) assessment. RECIST Criteria: CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm PR= ≥ 30% decrease in the sum of diameters of target lesions SD= does not qualify for PR or progressive disease RANO Criteria: CR= Disappearance of all enhancing disease; stable or improved nonenhancing T2/FLAIR lesions; off corticosteroids; and stable or improved clinically PR= ≥ 50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions; no progression of nonmeasureable disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions; stable or improved clinically SD= does not qualify for CR, PR, or progression; stable nonenhancing T2/FLAIR lesions
| Percentage of participants | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Blood TMB-H (bTMB-H) | 32.5 (22.4 to 43.9) | 28.9 (16.4 to 44.3) |
| Tissue TMB-H (tTMB-H) | 53.4 (42.5 to 64.1) | 38.3 (24.5 to 53.6) |
PFS is defined as the time from randomization date to the date of the first documented tumor progression, determined by investigator assessment, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: Progressive Disease (PD)= ≥ 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of ≥ 5 mm. RANO Criteria: PD= ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement obtained either at baseline or best response, on stable or increasing doses of corticosteroids; significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.
| Months | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Blood TMB-H (bTMB-H) | 2.99 (2.66 to 4.34) | 3.04 (2.79 to 5.36) |
| Tissue TMB-H (tTMB-H) | 8.15 (4.83 to 12.94) | 3.06 (2.79 to 10.91) |
PFS is defined as the time from randomization date to the date of the first documented tumor progression, determined by Blinded Independent Central Review (BICR) assessment, or death due to any cause, whichever occurs first. Calculated using KM method. RECIST Criteria: Progressive Disease (PD)= ≥ 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of ≥ 5 mm. RANO Criteria: PD= ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared with the smallest tumor measurement obtained either at baseline or best response, on stable or increasing doses of corticosteroids; significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy; any new lesion; clear clinical deterioration or clear progression of nonmeasurable disease.
| Months | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Blood TMB-H (bTMB-H) | 2.83 (2.33 to 2.99) | 2.83 (2.60 to 3.25) |
| Tissue TMB-H (tTMB-H) | 5.68 (3.19 to 11.60) | 2.83 (2.69 to 5.72) |
OS is defined as the time between the date of randomization and the date of death due to any cause. Participants who did not have a date of death were censored on the last date for which a participant was known to be alive. Calculated using KM method.
| Months | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Blood TMB-H (bTMB-H) | 8.07 (5.82 to 10.45) | 11.24 (5.26 to 18.99) |
| Tissue TMB-H (tTMB-H) | 16.48 (10.18 to 30.52) | 14.59 (7.69 to 18.23) |
Number of participants with any grade adverse events (AEs), serious adverse events (SAEs), drug-related AEs, and drug-related SAEs by Tumor Mutational Burden- High (TMB-H) status using worst grade per national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) v5 criteria. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. TMB-H = ≥ 10 mutations per megabase bTMB-H and tTMB-H are not mutually exclusive
| Participants | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Blood TMB-H (bTMB-H) AEs | 82 | 46 |
| Tissue TMB-H (tTMB-H) AEs | 93 | 50 |
| bTMB-H SAEs | 51 | 17 |
| tTMB-H SAEs | 46 | 16 |
| bTMB-H drug-related AEs | 64 | 29 |
| tTMB-H drug-related AEs | 78 | 27 |
| bTMB-H drug-related SAEs | 17 | 1 |
| tTMB-H drug-related SAEs | 16 | 2 |
Number of participants with grade 3-4 on-treatment laboratory parameters. Parameters include hematology, chemistry, liver function, and renal function using worst grade per national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) v5 criteria. Grade 3=Severe event Grade 4=Life threatening event TMB-H = ≥ 10 mutations per megabase bTMB-H and tTMB-H are not mutually exclusive
| Participants | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab |
|---|---|---|
| Blood TMB-H (bTMB-H) Hemoglobin grade 3 | 6 | 3 |
| Tissue TMB-H (tTMB-H) Hemoglobin grade 3 | 8 | 7 |
| Blood TMB-H (bTMB-H) Platelet Count grade 3-4 | 1 | 0 |
| Tissue TMB-H (tTMB-H) Platelet Count grade 3-4 | 0 | 1 |
| Blood TMB-H (bTMB-H) Leukocytes grade 3- 4 | 1 | 0 |
| Tissue TMB-H (tTMB-H) Leukocytes grade 3- 4 | 0 | 0 |
| Blood TMB-H (bTMB-H) Leukocytes Absolute grade 3- 4 | 2 | 1 |
| Tissue TMB-H (tTMB-H) Leukocytes Absolute grade 3- 4 | 5 | 3 |
| Blood TMB-H (bTMB-H) Absolute Neutrophil grade 3- 4 | 1 | 1 |
| Tissue TMB-H (tTMB-H) Absolute Neutrophil grade 3- 4 | 0 | 0 |
| Blood TMB-H (bTMB-H) Alkaline Phosphatase grade 3-4 | 2 | 1 |
| Tissue TMB-H (tTMB-H) Alkaline Phosphatase grade 3-4 | 2 | 0 |
| Blood TMB-H (bTMB-H) Aspartate Aminotransferase grade 3-4 | 2 | 3 |
| Tissue TMB-H (tTMB-H) Aspartate Aminotransferase grade 3-4 | 4 | 1 |
| Blood TMB-H (bTMB-H) Alanine Aminotransferase grade 3-4 | 5 | 2 |
| Tissue TMB-H (tTMB-H) Alanine Aminotransferase grade 3-4 | 3 | 1 |
| Blood TMB-H (bTMB-H) Bilirubin grade 3-4 | 3 | 2 |
| Tissue TMB-H (tTMB-H) Bilirubin grade 3-4 | 3 | 1 |
| Blood TMB-H (bTMB-H) Creatinine grade 3-4 | 3 | 1 |
| Tissue TMB-H (tTMB-H) Creatinine grade 3-4 | 3 | 0 |
| Blood TMB-H (bTMB-H) Hypernatremia grade 3-4 | 0 | 0 |
| Tissue TMB-H (tTMB-H) Hypernatremia grade 3-4 | 0 | 0 |
| Blood TMB-H (bTMB-H) Hyponatremia grade 3-4 | 4 | 1 |
| Tissue TMB-H (tTMB-H) Hyponatremia grade 3-4 | 3 | 1 |
| Blood TMB-H (bTMB-H) Hyperkalemia grade 3-4 | 2 | 0 |
| Tissue TMB-H (tTMB-H) Hyperkalemia grade 3-4 | 2 | 0 |
| Blood TMB-H (bTMB-H) Hypokalemia grade 3-4 | 4 | 0 |
| Tissue TMB-H (tTMB-H) Hypokalemia grade 3-4 | 3 | 1 |
| Blood TMB-H (bTMB-H) Hypercalcemia grade 3-4 | 0 | 1 |
| Tissue TMB-H (tTMB-H) Hypercalcemia grade 3-4 | 2 | 0 |
| Blood TMB-H (bTMB-H) Hypocalcemia grade 3-4 | 2 | 0 |
| Tissue TMB-H (tTMB-H) Hypocalcemia grade 3-4 | 0 | 1 |
| Blood TMB-H (bTMB-H) Hyperglycemia grade 3-4 | 0 | 0 |
| Tissue TMB-H (tTMB-H) Hyperglycemia grade 3-4 | 0 | 0 |
| Blood TMB-H (bTMB-H) Hypoglycemia grade 3-4 | 0 | 0 |
| Tissue TMB-H (tTMB-H) Hypoglycemia grade 3-4 | 0 | 0 |
Collected over SAEs and AEs are assessed from first dose to 100 days post last dose (Up to 27 months). Participants were assessed for all-cause mortality from their first dose to study completion (Up to 57 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Nivolumab+Ipilimumab | 97/136 (71.3%) | 90/135 (66.7%) | 121/135 (89.6%) |
| Arm B: Nivolumab | 42/76 (55.3%) | 39/76 (51.3%) | 64/76 (84.2%) |
| Arm B: Nivolumab+Ipilimumab (Rollover) | 20/22 (90.9%) | 11/22 (50%) | 13/22 (59.1%) |
| Event | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab | Arm B: Nivolumab+Ipilimumab (Rollover) |
|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 43/135 | 25/76 | 7/22 |
| UrosepsisInfections and infestations | 2/135 | 0/76 | 2/22 |
| ColitisGastrointestinal disorders | 4/135 | 0/76 | 1/22 |
| Gastric perforationGastrointestinal disorders | 1/135 | 0/76 | 1/22 |
| NauseaGastrointestinal disorders | 1/135 | 0/76 | 1/22 |
| MalaiseGeneral disorders | 0/135 | 0/76 | 1/22 |
| PyrexiaGeneral disorders | 5/135 | 0/76 | 1/22 |
| HepatitisHepatobiliary disorders | 1/135 | 0/76 | 1/22 |
| Prostate infectionInfections and infestations | 0/135 | 0/76 | 1/22 |
| Urinary tract infectionInfections and infestations | 3/135 | 1/76 | 1/22 |
| Event | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab | Arm B: Nivolumab+Ipilimumab (Rollover) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 50/135 | 14/76 | 3/22 |
| PruritusSkin and subcutaneous tissue disorders | 36/135 | 15/76 | 8/22 |
| FatigueGeneral disorders | 41/135 | 17/76 | 2/22 |
| AnaemiaBlood and lymphatic system disorders | 32/135 | 16/76 | 3/22 |
| Decreased appetiteMetabolism and nutrition disorders | 28/135 | 6/76 | 2/22 |
| NauseaGastrointestinal disorders | 19/135 | 15/76 | 4/22 |
| RashSkin and subcutaneous tissue disorders | 25/135 | 7/76 | 1/22 |
| Urinary tract infectionInfections and infestations | 12/135 | 2/76 | 4/22 |
| Abdominal painGastrointestinal disorders | 23/135 | 6/76 | 1/22 |
| ConstipationGastrointestinal disorders | 23/135 | 10/76 | 1/22 |
| Age, Continuous(Years) | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab | Total |
|---|---|---|---|
| Mean | 60.0 ± 11.7 | 57.6 ± 12.1 | 59.2 ± 11.9 |
| Sex: Female, Male(Participants) | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab | Total |
|---|---|---|---|
| Female | 71 | 44 | 115 |
| Male | 65 | 32 | 97 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 5 | 18 |
| Not Hispanic or Latino | 45 | 20 | 65 |
| Unknown or Not Reported | 78 | 51 | 129 |
| Race (NIH/OMB)(Participants) | Arm A: Nivolumab+Ipilimumab | Arm B: Nivolumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 3 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 124 | 60 | 184 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 12 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in May 2022, 42 months.
Results were first posted in May 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab